Provide first-time accuracy with direct MIC for trusted detection of emerging and critical antimicrobial resistance.
As the foundation of MicroScan ID/AST products, conventional panels deliver gold-standard1 accuracy with the fewest clinically significant reporting limitations of leading automated systems. This reduces the need for repeat testing, providing timely results without reliance on historical data.
Direct MIC Testing to Support Your Laboratory’s Antimicrobial Stewardship
The MicroScan portfolio of ID/AST panels supports unique institutional and geographic needs with a broad menu of antibiotic configurations and choice of inoculum preparation methods. With continued emergence of antimicrobial resistance, our direct MIC testing methodology provides confidence for detecting subtle changes in susceptibility results.
With our MicroScan Rapid ID panels, your laboratory can support proactive antimicrobial stewardship activities using your existing system.
MicroScan Rapid ID panels provide definitive identifications for routine and clinically significant organisms in as little as 2.5 hours. Rapid ID coupled with your hospital antibiogram provides rapid empirical therapy guidance when needed.
Our MicroScan Specialty ID Panels provide 4-hour identification (ID) results for routine yeast species, fastidious Gram-negative rods and anaerobic bacteria.
As yeast, fastidious organisms and anaerobes play a greater role in infectious disease, MicroScan Specialty ID panels meet the challenge. Choose from three panels for rapid identification of yeast, Haemophilus and Neisseria spp. and anaerobic bacteria. This technology tests for the presence of pre-formed enzymes used by the organism to metabolize various substrates.
MIC testing for all Streptococcus spp. using CLSI microdilution supplementation and incubation standards.
Healthcare professionals are faced with a variety of significant fastidious pathogens where resistance to an extensive number of antibiotics is rapidly on the rise. This can lead to complications, ranging from pediatric ear infections to life-threatening conditions, such as meningitis or sepsis. For appropriate antimicrobial therapy, accurate minimum inhibitory concentration (MIC) testing should be assessed for all significant isolates.
Get confirmation and susceptibility testing for ESβL-producing organisms using CLSI-recommended dilutions.
Resistance to a wide variety of common antimicrobials has made the spread of ESβL-producing strains a global health concern, and the CDC classifies them as a serious health threat. Although routine testing of clinical isolates for ESβL production is no longer required by the CLSI, testing is still useful for epidemiological or infection control purposes. Accurate detection of ESβL-producing organisms can be a clinical problem; timely detection is required for successful infection management.
|Product Division||Laboratory Division|
|Brand||Beckman Coulter - Microbiology|